NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

Phase 1

Completed

Conditions: Anal Cancer

Interventions: Biological: HspE7

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00052897

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: O6-benzylguanine
Drug: carmustine

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00005961

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 10 locations

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

Phase 1

Terminated

Conditions: Cervical Cancer
Cervical Intraepithelial Neoplasia Grade 2
Cervical Intraepithelial Neoplasia Grade 3

Interventions: Drug: motexafin lutetium
Procedure: loop electrosurgical excision procedure
Drug: photodynamic therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00005808

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

Interventions: Drug: hydroxyurea
Drug: fluorouracil
Biological: bevacizumab
Radiation: radiation therapy
Biological: filgrastim
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00023959

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: carboplatin
Drug: etoposide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00027898

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Decitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Male Breast Cancer
Recurrent Bladder Cancer
Recurrent Breast Cancer
Recurrent Melanoma
Stage III Melanoma
Stage IV Bladder Cancer
Stage IV Breast Cancer
Stage IV Melanoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: decitabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00030615

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Undifferentiated Leukemia
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blastic Phase Chronic Myelogenous Leukemia
Childhood Myelodysplastic Syndromes
Chronic Eosinophilic Leukemia

Interventions: Drug: imatinib mesylate
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00025415

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase 1

Completed

Conditions: Adult Glioblastoma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma

Interventions: Drug: tipifarnib
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00049387

Locations: 🇺🇸
Adult Brain Tumor Consortium, Baltimore, Maryland, United States

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Phase 3

Completed

Conditions: Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Adenocarcinoma of the Lung
Squamous Cell Lung Cancer
Adenosquamous Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer

Interventions: Other: placebo
Drug: gefitinib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2015-01-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 503

Registration Number: NCT00049543

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Recurrent Adult Brain Tumor
Adult Anaplastic Oligodendroglioma
Adult Glioblastoma
Adult Gliosarcoma
Adult Grade I Meningioma
Adult Grade III Meningioma
Adult Grade II Meningioma
Adult Anaplastic Astrocytoma

Interventions: Drug: erlotinib hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2017-08-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 136

Registration Number: NCT00045110

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Home Terms & Conditions Privacy Policy